PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för goralatide. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

42 hits

Bibliografisk träff 2022-06-22

An analytical quality by design approach towards a simple and novel HPLC-UV method for quantification of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline.

Ho HMK, Sembi S, Abukhamees S, Day RM, Craig DQM.

Anal Biochem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ab.2022.114793

Bibliografisk träff 2022-02-01

Urine N-acetyl-Ser-Asp-Lys-Pro measurement as a versatile biomarker to assess adherence to angiotensin-converting enzyme inhibitors.

Kably B, Billaud EM, Derobertmasure A, Blanchard A, Boutouyrie P, Azizi M.

J Hypertens · research support, non-u.s. gov't; journal article · DOI 10.1097/hjh.0000000000003018

Bibliografisk träff 2022-02-01

[Regulatory effect of Ac-SDKP on phosphorylated heat shock protein 27/SNAI1 pathway in silicotic rats].

Cao W, Yao SS, Gong HB, Zhu LY, Miao ZY, Deng HJ.

Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi · journal article · DOI 10.3760/cma.j.cn121094-20201218-00702

Bibliografisk träff 2022-01-15

Ac-SDKP peptide improves functional recovery following spinal cord injury in a preclinical model.

Hashemizadeh S, Pourkhodadad S, Hosseindoost S, Pejman S, Kamarehei M, Badripour A, Omidi A, Pestehei SK, Seifalian AM, Hadjighassem M.

Neuropeptides · journal article · DOI 10.1016/j.npep.2022.102228

Bibliografisk träff 2021-12-16

N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) mitigates the liver fibrosis via WTAP/m6A/Ptch1 axis through Hedgehog pathway.

Wei A, Zhao F, Hao A, Liu B, Liu Z.

Gene · journal article · DOI 10.1016/j.gene.2021.146125

Bibliografisk träff 2021-10-01

High-volume endurance exercise training stimulates hematopoiesis by increasing ACE NH2-terminal activity.

Magalhães FC, Fernandes T, Bassaneze V, Mattos KC, Schettert I, Marques FLN, Krieger JE, Nava R, Barauna VG, Menezes de Oliveira E.

Clin Sci (Lond) · research support, non-u.s. gov't; journal article · DOI 10.1042/cs20210739

Bibliografisk träff 2021-09-17

Glycolytic Reprogramming in Silica-Induced Lung Macrophages and Silicosis Reversed by Ac-SDKP Treatment.

Mao N, Yang H, Yin J, Li Y, Jin F, Li T, Yang X, Sun Y, Liu H, Xu H, Yang F.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms221810063

Bibliografisk träff 2021-08-18

Investigating the antifibrotic potential of N-acetyl seryl-aspartyl-lysyl-proline sequence peptides.

Ramasamy V, Ntsekhe M, Sturrock E.

Clin Exp Pharmacol Physiol · journal article · DOI 10.1111/1440-1681.13565

Bibliografisk träff 2021-04-27

Ac-SDKP Attenuates Activation of Lung Macrophages and Bone Osteoclasts in Rats Exposed to Silica by Inhibition of TLR4 and RANKL Signaling Pathways.

Jin F, Geng F, Xu D, Li Y, Li T, Yang X, Liu S, Zhang H, Wei Z, Li S, Gao X, Cai W, Mao N, Yi X, Liu H, Sun Y, Yang F, Xu H.

J Inflamm Res · research-article; journal article · DOI 10.2147/jir.s306883

Bibliografisk träff 2021-03-10

Angiotensin-converting enzyme inhibitors increase anti-fibrotic biomarkers in African Americans with left ventricular hypertrophy.

A Romero C, Mathew S, Wasinski B, Reed B, Brody A, Dawood R, Twiner MJ, McNaughton CD, Fridman R, Flack JM, Carretero OA, Levy PD.

J Clin Hypertens (Greenwich) · research-article; randomized controlled trial; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1111/jch.14206

Bibliografisk träff 2020-11-02

A long-acting isomer of Ac-SDKP attenuates pulmonary fibrosis through SRPK1-mediated PI3K/AKT and Smad2 pathway inhibition.

Qiu Y, Wang Z, Zhang X, Huang P, Zhang W, Zhang K, Wang S, He L, Guo Y, Xiang A, Zhang C, Hao Q, Li M, Li W, Zhang Y.

IUBMB Life · research support, non-u.s. gov't; journal article · DOI 10.1002/iub.2389

Bibliografisk träff 2020-06-22

Metabolic reprogramming by N-acetyl-seryl-aspartyl-lysyl-proline protects against diabetic kidney disease.

Srivastava SP, Goodwin JE, Kanasaki K, Koya D.

Br J Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/bph.15087

Bibliografisk träff 2020-05-06

N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Mitigates Experimental Colitis Through Inhibition of Intestinal Mucosal Inflammatory Responses via MEK-ERK Signaling.

Shi Y, Zhou M, Yan J, Gong Z, Wu J, Chen Y, Chen Y.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2020.00593

Bibliografisk träff 2020-03-11

N-acetyl-seryl-aspartyl-lysyl-proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects.

Kanasaki K.

J Diabetes Investig · review-article; review; journal article · DOI 10.1111/jdi.13219

Bibliografisk träff 2019-08-13

Interaction of N-acetyl-seryl-aspartyl-lysyl-proline with the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis attenuates pulmonary fibrosis in silicotic rats.

Gao X, Xu H, Zhang B, Tao T, Liu Y, Xu D, Cai W, Wei Z, Li S, Zhang H, Mao N, Zhang G, Li D, Jin F, Li S, Zhang L, Liu H, Hao X, Yang F.

Exp Physiol · research support, non-u.s. gov't; journal article · DOI 10.1113/ep087515

Bibliografisk träff 2019-08-07

N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments Thrombolysis of tPA (Tissue-Type Plasminogen Activator) in Aged Rats After Stroke.

Li C, Zhang L, Wang C, Teng H, Fan B, Chopp M, Zhang ZG.

Stroke · research-article; journal article; research support, n.i.h., extramural · DOI 10.1161/strokeaha.119.026212

Bibliografisk träff 2019-04-22

βklotho is essential for the anti-endothelial mesenchymal transition effects of N-acetyl-seryl-aspartyl-lysyl-proline.

Gao R, Kanasaki K, Li J, Kitada M, Okazaki T, Koya D.

FEBS Open Bio · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/2211-5463.12638

Bibliografisk träff 2019-04-18

N-acetyl-seryl-aspartyl-lysyl-proline treatment protects heart against excessive myocardial injury and heart failure in mice.

Peng H, Xu J, Yang XP, Kassem KM, Rhaleb IA, Peterson E, Rhaleb NE.

Can J Physiol Pharmacol · research-article; journal article · DOI 10.1139/cjpp-2019-0047

Bibliografisk träff 2019-04-04

N-Acetyl-seryl-aspartyl-lysyl-proline is a potential biomarker of renal function in normoalbuminuric diabetic patients with eGFR ≥ 30 ml/min/1.73 m2.

Nitta K, Nagai T, Mizunuma Y, Kitada M, Nakagawa A, Sakurai M, Toyoda M, Haneda M, Kanasaki K, Koya D.

Clin Exp Nephrol · journal article · DOI 10.1007/s10157-019-01733-6

Bibliografisk träff 2019-03-21

d-amino acid modification protects N-Acetyl-seryl-aspartyl-lysyl-proline from physiological hydroxylation and increases its antifibrotic effects on hepatic fibrosis.

Zhang X, Zhou J, Zhu Y, He L, Pang Z, Wang Z, Xu C, Zhang C, Hao Q, Li W, Zhang W, Zhang Y, Li M.

IUBMB Life · research support, non-u.s. gov't; journal article · DOI 10.1002/iub.2037

Bibliografisk träff 2019-02-28

Ac-SDKP increases α-TAT 1 and promotes the apoptosis in lung fibroblasts and epithelial cells double-stimulated with TGF-β1 and silica.

Shifeng L, Hong X, Xue Y, Siyu N, Qiaodan Z, Dingjie X, Lijuan Z, Zhongqiu W, Xuemin G, Wenchen C, Guizhen Z, Dan L, Ruimin W, Fang Y.

Toxicol Appl Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.taap.2019.02.015

Bibliografisk träff 2018-11-07

Renal release of N-acetyl-seryl-aspartyl-lysyl-proline is part of an antifibrotic peptidergic system in the kidney.

Romero CA, Kumar N, Nakagawa P, Worou ME, Liao TD, Peterson EL, Carretero OA.

Am J Physiol Renal Physiol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1152/ajprenal.00270.2018

Bibliografisk träff 2018-07-07

The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases.

Kumar N, Yin C.

Pharmacol Res · review; journal article · DOI 10.1016/j.phrs.2018.07.006

Bibliografisk träff 2018-07-01

Renal Protective Effects of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) in Obese Rats on a High-Salt Diet.

Maheshwari M, Romero CA, Monu SR, Kumar N, Liao TD, Peterson EL, Carretero OA.

Am J Hypertens · research-article; journal article; research support, n.i.h., extramural · DOI 10.1093/ajh/hpy052

Bibliografisk träff 2018-04-22

N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) attenuates silicotic fibrosis by suppressing apoptosis of alveolar type II epithelial cells via mediation of endoplasmic reticulum stress.

Zhang L, Xu D, Li Q, Yang Y, Xu H, Wei Z, Wang R, Zhang W, Liu Y, Geng Y, Li S, Gao X, Yang F.

Toxicol Appl Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.taap.2018.04.025

Bibliografisk träff 2018-04-01

N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.

Chan GCW, Wu HJ, Chan KW, Yiu WH, Zou A, Huang XR, Lan HY, Lai KN, Tang SCW.

Nephrology (Carlton) · journal article · DOI 10.1111/nep.13000

Bibliografisk träff 2018-03-29

Influence of the interaction between Ac‑SDKP and Ang II on the pathogenesis and development of silicotic fibrosis.

Zhang Y, Yang F, Liu Y, Peng HB, Geng YC, Li SF, Xu H, Zhu LY, Yang XH, Brann D.

Mol Med Rep · research-article; journal article · DOI 10.3892/mmr.2018.8824

Bibliografisk träff 2017-12-18

FGFR1 is essential for N-acetyl-seryl-aspartyl-lysyl-proline regulation of mitochondrial dynamics by upregulating microRNA let-7b-5p.

Hu Q, Li J, Nitta K, Kitada M, Nagai T, Kanasaki K, Koya D.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2017.12.089

Bibliografisk träff 2017-08-03

FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N-acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway.

Li J, Shi S, Srivastava SP, Kitada M, Nagai T, Nitta K, Kohno M, Kanasaki K, Koya D.

Cell Death Dis · research-article; journal article · DOI 10.1038/cddis.2017.353

Bibliografisk träff 2016-08-31

Acetylated α-Tubulin Regulated by N-Acetyl-Seryl-Aspartyl-Lysyl-Proline(Ac-SDKP) Exerts the Anti-fibrotic Effect in Rat Lung Fibrosis Induced by Silica.

Xiaojun W, Yan L, Hong X, Xianghong Z, Shifeng L, Dingjie X, Xuemin G, Lijuan Z, Bonan Z, Zhongqiu W, Ruimin W, Brann D, Fang Y.

Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/srep32257

Go to research.

Publications in the selection

An analytical quality by design approach towards a simple and novel HPLC-UV method for quantification of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline.

Urine N-acetyl-Ser-Asp-Lys-Pro measurement as a versatile biomarker to assess adherence to angiotensin-converting enzyme inhibitors.

[Regulatory effect of Ac-SDKP on phosphorylated heat shock protein 27/SNAI1 pathway in silicotic rats].

Ac-SDKP peptide improves functional recovery following spinal cord injury in a preclinical model.

N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) mitigates the liver fibrosis via WTAP/m<sup>6</sup>A/Ptch1 axis through Hedgehog pathway.

High-volume endurance exercise training stimulates hematopoiesis by increasing ACE NH2-terminal activity.

Glycolytic Reprogramming in Silica-Induced Lung Macrophages and Silicosis Reversed by Ac-SDKP Treatment.

Investigating the antifibrotic potential of N-acetyl seryl-aspartyl-lysyl-proline sequence peptides.

Ac-SDKP Attenuates Activation of Lung Macrophages and Bone Osteoclasts in Rats Exposed to Silica by Inhibition of TLR4 and RANKL Signaling Pathways.

Angiotensin-converting enzyme inhibitors increase anti-fibrotic biomarkers in African Americans with left ventricular hypertrophy.

A long-acting isomer of Ac-SDKP attenuates pulmonary fibrosis through SRPK1-mediated PI3K/AKT and Smad2 pathway inhibition.

Metabolic reprogramming by N-acetyl-seryl-aspartyl-lysyl-proline protects against diabetic kidney disease.

N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Mitigates Experimental Colitis Through Inhibition of Intestinal Mucosal Inflammatory Responses <i>via</i> MEK-ERK Signaling.

N-acetyl-seryl-aspartyl-lysyl-proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects.

Interaction of N-acetyl-seryl-aspartyl-lysyl-proline with the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis attenuates pulmonary fibrosis in silicotic rats.

N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments Thrombolysis of tPA (Tissue-Type Plasminogen Activator) in Aged Rats After Stroke.

βklotho is essential for the anti-endothelial mesenchymal transition effects of N-acetyl-seryl-aspartyl-lysyl-proline.

<i>N</i>-acetyl-seryl-aspartyl-lysyl-proline treatment protects heart against excessive myocardial injury and heart failure in mice.

N-Acetyl-seryl-aspartyl-lysyl-proline is a potential biomarker of renal function in normoalbuminuric diabetic patients with eGFR ≥ 30 ml/min/1.73 m<sup>2</sup>.

d-amino acid modification protects N-Acetyl-seryl-aspartyl-lysyl-proline from physiological hydroxylation and increases its antifibrotic effects on hepatic fibrosis.

Ac-SDKP increases α-TAT 1 and promotes the apoptosis in lung fibroblasts and epithelial cells double-stimulated with TGF-β1 and silica.

Renal release of N-acetyl-seryl-aspartyl-lysyl-proline is part of an antifibrotic peptidergic system in the kidney.

The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases.

Renal Protective Effects of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) in Obese Rats on a High-Salt Diet.

N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) attenuates silicotic fibrosis by suppressing apoptosis of alveolar type II epithelial cells via mediation of endoplasmic reticulum stress.

N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.

Influence of the interaction between Ac‑SDKP and Ang II on the pathogenesis and development of silicotic fibrosis.

FGFR1 is essential for N-acetyl-seryl-aspartyl-lysyl-proline regulation of mitochondrial dynamics by upregulating microRNA let-7b-5p.

FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N-acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway.

Acetylated α-Tubulin Regulated by N-Acetyl-Seryl-Aspartyl-Lysyl-Proline(Ac-SDKP) Exerts the Anti-fibrotic Effect in Rat Lung Fibrosis Induced by Silica.